How a dual-register informed consent form for a Phase 3 neurodegenerative trial was delivered in French for ANSM and FAMHP without a country-specific revision cycle.
The client
A pharmaceutical sponsor conducting a Phase 3 investigational antibody trial in early symptomatic neurodegenerative disease, recruiting in both France and Belgium. The informed consent form was required in French for two distinct regulatory authorities – ANSM and FAMHP – each with different consent clause requirements for their jurisdictions.
The challenge
This project required the translation of a 40-page document that combined two different communication registers: legal consent language and accessible patient summary sections. This posed a very specific translation challenge, to translate two different registers correctly while maintaining a separation between them. The consent sections required the weight and precision of a legal document. The patient summary sections needed to be accessible and easy to understand for someone who had never read a clinical trial document.
The risk in translation was not getting the content wrong in either register – it was letting the two bleed into each other. A consent clause that softens into accessibility loses its legal force. A patient summary that tightens into consent language loses its purpose. Both had to hold, throughout 40 pages, in two different variants of the French language.
The jurisdictional layer added another dimension. ANSM and FAMHP require different formulations for certain consent clauses. Discovering those differences during review rather than before translation would have meant a full country-specific revision cycle after delivery.
The solution
Before translation began, we carried out a clause-by-clause analysis of the source document to identify every section that would require country-specific handling. The result was an annotation in the source document itself – each clause highlighted the required ANSM and FAMHP formulation difference. The sponsor’s input was paramount before any work commenced so jurisdictional decisions were confirmed upstream rather than surfacing during review.
Throughout the translation, both registers were treated as a single coherent task rather than two separate passes. All PLS language sections were then verified against the EFPIA Lay Summary Handbook and the EC GLSP guidance (October 2021), with a compliance note delivered alongside the target file.
The results
- Register integrity maintained throughout: consent and patient summary sections each held their required French register without drift across the full 40-page document.
- ANSM and FAMHP consent clause differences resolved during pre-translation analysis – no country-specific revision cycle required after delivery.
- All PLS language sections verified against the EFPIA Lay Summary Handbook and GLSP guidance (EC October 2021) before delivery.
- Compliance note provided alongside the target file.
